Stüve-Wiedemann syndrome: LIFR and associated cytokines in clinical course and etiology

Orphanet Journal of Rare Diseases

Volumn 9, Issue 1, 2014, Pages

  Mikelonis, Dawn ^a   Jorcyk, Cheryl L ^a   Tawara, Ken ^a   Oxford, Julia Thom ^a  

^a BOISE STATE UNIVERSITY   (United States)

Author keywords

Leukemia inhibitory factor receptor; LIF; LIFR; St ve Wiedemann syndrome

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; AMINOGLYCOSIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARDIOTROPHIN 1; CILIARY NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR RECEPTOR; COMPLEMENT COMPONENT C9; DISABLED 2 PROTEIN; EYE DROPS; FYN BINDING PROTEIN; INTERLEUKIN 6; JANUS KINASE; LEUKEMIA INHIBITORY FACTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR; ONCOSTATIN M RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN; STAT3 PROTEIN; TROPICAMIDE; UNCLASSIFIED DRUG;

BONE DEVELOPMENT; BONE DYSPLASIA; CELL DIFFERENTIATION; FEEDING DIFFICULTY; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HYPERTHERMIA; MOTONEURON; MYOBLAST; MYOTONIA; OSTEOPENIA; RARE DISEASE; RESPIRATORY DISTRESS; REVIEW; SHORT STATURE; SIGNAL TRANSDUCTION; SPINE SURGERY; STUVE WIEDEMANN SYNDROME;

CYTOKINES; EXOSTOSES, MULTIPLE HEREDITARY; HUMANS; INFANT, NEWBORN; LEUKEMIA INHIBITORY FACTOR RECEPTOR ALPHA SUBUNIT; MUTATION; OSTEOCHONDRODYSPLASIAS; SIGNAL TRANSDUCTION;

EID: 84899462646     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-9-34     Document Type: Review

References (123)

1. Congenital bowing of the long bones in two sisters. Stuve A, Wiedemann HR, Lancet 1971 2 495
2. StüveWiedemann syndrome: update and historical footnote. Wiedemann H, Stueve A, Am J Med Genet 1996 63 12 16 10.1002/(SICI)1096-8628(19960503)63: 1<12::AID-AJMG5>3.0.CO;2-U 8723080
3. Longterm survival in StuveWiedemann syndrome: a neuromyoskeletal disorder with manifestations of dysautonomia. Rocco MD, Stella G, Am J Med Genet 2003 118A 362 368 10.1002/ajmg.a.10242 12687669
4. Delayed tetraplegia after thoracolumnbar scoliosis surgery in Stuve-Wiedemann syndrome. Pizones J, Sponseller PD, Izquirdo E, Sanz E, Sanchez-Martinez F, Alvarez P, Zuniga L, Spine Deform 2013 1 72 78 10.1016/j.jspd.2012.08.001
5. Characterization of a longterm survivor with StüveWiedemann syndrome and mosaicism of a supernumerary marker chromosome. Chen E, Cotter P, Am J Med Genet 2001 101 240 245 10.1002/ajmg.1382 11424139
6. SchwartzJampel syndrome type 2 and StüveWiedemann syndrome: a case for "Lumping" SupertiFurga A, Tenconi R, Am J Med Genet 1998 78 150 154 10.1002/(SICI)1096-8628(19980630)78:2<150::AID-AJMG10>3.0.CO;2-M 9674906
7. Null Leukemia Inhibitory Factor Receptor (LIFR) Mutations in Stüve-Wiedemann/Schwartz-Jampel Type 2 Syndrome. Dagoneau N, Scheffer D, Huber C, Al-Gazali LI, Di Rocco M, Godard A, Martinovic J, Raas-Rothschild A, Sigaudy S, Unger S, Nicole S, Fontaine B, Taupin J-L, Moreau J-F, Superti-Furga A, Le Merrer M, Bonaventure J, Munnich A, Legeai-Mallet L, Cormier-Daire V, Am J Hum Genet 2004 74 298 305 10.1086/381715 14740318
8. Mutations in Cytokine Receptor-Like Factor 1 (CRLF1) Account for Both Crisponi and Cold-Induced Sweating Syndromes. Dagoneau N, Bellais S, Blanchet P, Am J Hum Genet 2007 80 966 970 10.1086/513608 17436251
9. Crisponi Syndrome Is Caused by Mutations in the CRLF1 Gene and Is Allelic to Cold-Induced Sweating Syndrome Type 1. Crisponi L, Crisponi G, Meloni A, Am J Hum Genet 2007 80 971 981 10.1086/516843 17436252
10. Are there febrile diseases with a risk of sudden death in children? Rigante D, Arch Dis Child 2012 97 180
11. Nosology and classification of genetic skeletal disorders: 2010 revision. Warman ML, Cormier-Daire V, Hall C, Krakow D, Lachman R, LeMerrer M, Mortier G, Mundlos S, Nishimura G, Rimoin DL, Robertson S, Savarirayan R, Sillence D, Spranger J, Unger S, Zabel B, Superti-Furga A, Am J Med Genet A 2011 155A 943 968 21438135
12. Stüve-Wiedemann syndrome in children surviving infancy: clinical and radiological features. Al-Gazali LI, Ravenscroft A, Feng A, Shubbar A, Al-Saggaf A, Haas D, Clin Dysmorphol 2003 12 1 8 10.1097/00019605-200301000- 00001 12514358
13. Stuve-Wiedemann syndrome: long-term follow-up and genetic heterogeneity. Jung C, Dagoneau N, Baujat G, Merrer M, David A, Rocco M, Hamel B, Megarbane A, Superti-Furga A, Unger S, Munnich A, Cormier-Daire V, Clin Genet 2010 77 266 272 10.1111/j.1399-0004.2009.01314.x 20447141
14. Mutations of a country: a mutation review of single gene disorders in the United Arab Emirates (UAE). Al-Gazali L, Ali BR, Hum Mutat 2010 31 505 520 10.1002/humu.21232 20437613
15. One in three: congenital bent bone disease and intermittent hyperthermia in three siblings with stuve-wiedemann syndrome. Koul R, Al-Kindy A, Mani R, Sankhla D, Al-Futaisi A, Sultan Qaboos Univ Med J 2013 13 301 305 23862038
16. Presentation of six cases of Stüve-Wiedemann syndrome. Cormier-Daire V, Munnich A, Lyonnet S, Rustin P, Delezoide AL, Maroteaux P, Le Merrer M, Pediatr Radiol 1998 28 776 780 10.1007/s002470050464 9799300
17. Stuve Wiedemann syndrome and related syndromes: case report and possible anesthetic complications. Bonthuis D, Morava E, Paediatr Anesth 2009 19 212 217 10.1111/j.1460-9592.2008.02891.x
18. Abnormal oral-pharyngeal swallowing as cause of morbidity and early death in Stüve-Wiedemann syndrome. Corona-Rivera JR, Cormier-Daire V, Dagoneau N, Coello-Ramírez P, López-Marure E, Romo-Huerta CO, Silva-Baez H, Aguirre-Salas LM, Estrada-Solorio MI, Eur J Med Genet 2009 52 242 246 10.1016/j.ejmg.2009.04.001 19371797
19. Congenital contractures and distinctive phenotypic features consistent with Stuve-Wiedmann syndrome in a male infant. Kaissi A, Rumpler M, Csepan R, Grill F, Klaushofer K, Cases J 2008 1 121 10.1186/1757-1626-1-121 18718019
20. Stuve-Wiedemann syndrome: a skeletal dysplasia characterized by bowed long bones. Begam M a, Alsafi W, Bekdache GN, Chedid F, Al-Gazali L, Mirghani HM, Ultrasound Obstet Gynecol 2011 38 553 558 10.1002/uog.8967 21337444
21. Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. Ware CB, Horowitz MC, Renshaw BR, Hunt JS, Liggitt D, Koblar SA, Gliniak BC, McKenna HJ, Papayannopoulou T, Thoma B, Development 1995 121 1283 1299 7789261
22. Structure of the gene encoding the human differentiation-stimulating factor/leukemia inhibitory factor receptor. Tomida M, Gotoh O, J Biochem 1996 120 201 205 10.1093/oxfordjournals.jbchem.a021386 8864865
23. Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130. Gearing DP, Thut CJ, VandeBos T, Gimpel SD, Delaney PB, King J, Price V, Cosman D, Beckmann MP, EMBO J 1991 10 2839 2848 1915266
24. Pikachurin, a dystroglycan ligand, is essential for photoreceptor ribbon synapse formation. Sato S, Omori Y, Katoh K, Kondo M, Kanagawa M, Miyata K, Funabiki K, Koyasu T, Kajimura N, Miyoshi T, Sawai H, Kobayashi K, Tani A, Toda T, Usukura J, Tano Y, Fujikado T, Furukawa T, Nat Neurosci 2008 11 923 931 10.1038/nn.2160 18641643
25. Generalized epilepsy in two patients with 5p duplication. Kluger G, Koehler U, Neuhann TM, Pieper T, Staudt M, von Stülpnagel C, Neuropediatrics 2013 44 225 229 10.1055/s-0033-1333872 23483447
26. Disabled-2 protein facilitates assembly polypeptide-2-independent recruitment of cystic fibrosis transmembrane conductance regulator to endocytic vesicles in polarized human airway epithelial cells. Cihil KM, Ellinger P, Fellows A, Stolz DB, Madden DR, Swiatecka-Urban A, J Biol Chem 2012 287 15087 15099 10.1074/jbc.M112.341875 22399289
27. Context-dependent proangiogenic function of bone morphogenetic protein signaling is mediated by disabled homolog 2. Kim J-D, Kang H, Larrivée B, Lee MY, Mettlen M, Schmid SL, Roman BL, Qyang Y, Eichmann A, Jin S-W, Dev Cell 2012 23 441 448 10.1016/j.devcel.2012.07.007 22898784
28. Evaluation of the role of Disabled-2 in nerve growth factor-mediated neurite outgrowth and cellular signalling. Huang C-H, Cheng J-C, Chen J-C, Tseng C-P, Cell Signal 2007 19 1339 1347 10.1016/j.cellsig.2007.01.019 17317100
29. Complement proteins are present in developing endochondral bone and may mediate cartilage cell death and vascularization. Andrades JA, Nimni ME, Becerra J, Eisenstein R, Davis M, Sorgente N, Exp Cell Res 1996 227 208 213 10.1006/excr.1996.0269 8831558
30. The three-way relationship of polymorphisms of porcine genes encoding terminal complement components, their differential expression, and health-related phenotypes. Wimmers K, Khoa DVA, Schütze S, Murani E, Ponsuksili S, BMC Proc 2011 5 Suppl 4 19 21645298
31. Studies on demyelination in vitro: the requirement of membrane attack components of the complement system. Liu WT, Vanguri P, Shin ML, J Immunol 1983 131 778 782 6863930
32. Fyn positively regulates the activation of DAP12 and FcRγ-mediated costimulatory signals by RANKL during osteoclastogenesis. Kim HS, Kim DK, Kim AR, Mun SH, Lee SK, Kim JH, Kim YM, Choi WS, Cell Signal 2012 24 1306 1314 10.1016/j.cellsig.2012.02.014 22387224
33. Fyn mediates transforming growth factor-beta1-induced down-regulation of E-cadherin in human A549 lung cancer cells. Kim AN, Jeon W-K, Lim K-H, Lee H-Y, Kim WJ, Kim B-C, Biochem Biophys Res Commun 2011 407 181 184 10.1016/j.bbrc.2011.02.134 21371426
34. Duffy locus linkage and HLA antigens in hereditary motor-sensory neuropathy. Nevsímalová S, Prazák J, Herzog P, Seemanová E, Schweiz Arch Neurol Psychiatr 1991 142 19 29 1709295
35. Targeted disruption of oncostatin M receptor results in altered hematopoiesis. Tanaka M, Hirabayashi Y, Sekiguchi T, Inoue T, Katsuki M, Miyajima A, Blood 2003 102 3154 3162 10.1182/blood-2003-02-0367 12855584
36. Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. Walker EC, McGregor NE, Poulton IJ, Solano M, Pompolo S, Fernandes TJ, Constable MJ, Nicholson GC, Zhang J-G, Nicola NA, Gillespie MT, Martin TJ, Sims NA, J Clin Invest 2010 120 582 592 10.1172/JCI40568 20051625
37. Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas. Chen D, Chu C-Y, Chen C-Y, Yang H-C, Chiang Y-Y, Lin T-Y, Chiang I-P, Chuang D-Y, Yu C-C, Chow K-C, J Pathol 2008 215 290 299 10.1002/path.2361 18491353
38. Oncostatin M in the development of the nervous system. Morikawa Y, Anat Sci Int 2005 80 53 59 10.1111/j.1447-073x.2005.00100.x 15794131
39. Lack of oncostatin M receptor β leads to adipose tissue inflammation and insulin resistance by switching macrophage phenotype. Komori T, Tanaka M, Senba E, Miyajima A, Morikawa Y, J Biol Chem 2013 288 21861 21875 10.1074/jbc.M113.461905 23760275
40. Molecular cloning and expression of the human homologue of the murine gene encoding myeloid leukemia-inhibitory factor. Gough NM, Gearing DP, King JA, Willson TA, Hilton DJ, Nicola NA, Metcalf D, Proc Natl Acad Sci U S A 1988 85 2623 2627 10.1073/pnas.85.8.2623 3128791
41. Molecular cloning, sequence analysis, and functional expression of a novel growth regulator, oncostatin M. Malik N, Kallestad JC, Gunderson NL, Austin SD, Neubauer MG, Ochs V, Marquardt H, Zarling JM, Shoyab M, Wei CM, Mol Cell Biol 1989 9 2847 2853 2779549
42. Human cardiotrophin-1: protein and gene structure, biological and binding activities, and chromosomal localization. Pennica D, Swanson TA, Shaw KJ, Kuang WJ, Gray CL, Beatty BG, Wood WI, Cytokine 1996 8 183 189 10.1006/cyto.1996.0026 8833032
43. Molecular cloning, expression and regional distribution of rat ciliary neurotrophic factor. Stöckli KA, Lottspeich F, Sendtner M, Masiakowski P, Carroll P, Götz R, Lindholm D, Thoenen H, Nature 1989 342 920 923 10.1038/342920a0 2594085
44. Interactions between oncostatin M and the IL-6 signal transducer, gp130. Liu J, Modrell B, Aruffo A, Scharnowske S, Shoyab M, Cytokine 1994 6 272 278 10.1016/1043-4666(94)90023-X 8054483
45. Oncostatin M binds the high-affinity leukemia inhibitory factor receptor. Gearing DP, Bruce AG, New Biol 1992 4 61 65 1536831
46. The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Gearing DP, Comeau MR, Friend DJ, Gimpel SD, Thut CJ, McGourty J, Brasher KK, King JA, Gillis S, Mosley B, Science 1992 255 1434 1437 10.1126/science.1542794 1542794
47. Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. Mosley B, De Imus C, Friend D, Boiani N, Thoma B, Park LS, Cosman D, J Biol Chem 1996 271 32635 32643 10.1074/jbc.271.51.32635 8999038
48. Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series VIA gp130/leukemia inhibitory factor receptor-dependent pathways. Wollert KC, Taga T, Saito M, Narazaki M, Kishimoto T, Glembotski CC, Vernallis AB, Heath JK, Pennica D, Wood WI, Chien KR, J Biol Chem 1996 271 9535 9545 10.1074/jbc.271.16.9535 8621626
49. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F, Biochem J 2003 374 1 20 10.1042/BJ20030407 12773095
50. Transregulation of leukemia inhibitory [corrected] factor receptor expression and function by growth factors in neuroblastoma cells. Port MD, Laszlo GS, Nathanson NM, J Neurochem 2008 106 1941 1951 18624908
51. CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex. Elson GC, Lelièvre E, Guillet C, Chevalier S, Plun-Favreau H, Froger J, Suard I, de Coignac AB, Delneste Y, Bonnefoy JY, Gauchat JF, Gascan H, Nat Neurosci 2000 3 867 872 10.1038/78765 10966616
52. The tripartite CNTF receptor complex: activation and signaling involves components shared with other cytokines. Stahl N, Yancopoulos GD, J Neurobiol 1994 25 1454 1466 10.1002/neu.480251111 7852997
53. Dimerization of the cytokine receptors gp130 and LIFR analysed in single cells. Giese B, Roderburg C, Sommerauer M, Wortmann SB, Metz S, Heinrich PC, Müller-Newen G, J Cell Sci 2005 118 5129 5140 10.1242/jcs.02628 16254248
54. Activation of JAK-STAT and MAP kinases by leukemia inhibitory factor through gp130 in cardiac myocytes. Kunisada K, Hirota H, Fujio Y, Matsui H, Tani Y, Yamauchi-Takihara K, Kishimoto T, Circulation 1996 94 2626 2632 10.1161/01.CIR.94.10.2626 8921810
55. In vitro readthrough of termination codons by gentamycin in the Stüve-Wiedemann Syndrome. Bellais S, Goff C, Dagoneau N, Munnich A, Cormier-Daire V, Eur J Hum Genet 2010 18 130 132 10.1038/ejhg.2009.122 19603067
56. Induction of gp130-related cytokines and activation of JAK2/STAT3 pathway in astrocytes precedes up-regulation of glial fibrillary acidic protein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of neurodegeneration: key signaling pathway for ast. Sriram K, Benkovic SA, Hebert MA, Miller DB, O'Callaghan JP, J Biol Chem 2004 279 19936 19947 10.1074/jbc.M309304200 14996842
57. Extracellular signal-dependent nuclear import of Stat1 is mediated by nuclear pore-targeting complex formation with NPI-1, but not Rch1. Sekimoto T, Imamoto N, Nakajima K, Hirano T, Yoneda Y, EMBO J 1997 16 7067 7077 10.1093/emboj/16.23.7067 9384585
58. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. Sims NA, Jenkins BJ, Quinn JMW, Nakamura A, Glatt M, Gillespie MT, Ernst M, Martin TJ, J Clin Invest 2004 113 379 389 10.1172/JCI19872 14755335
59. Box 3-independent signaling mechanisms are involved in leukemia inhibitory factor receptor alpha- and gp130-mediated stimulation of mitogen-activated protein kinase. Evidence for participation of multiple signaling pathways which converge at Ras. Schiemann WP, Bartoe JL, Nathanson NM, J Biol Chem 1997 272 16631 16636 10.1074/jbc.272.26.16631 9195977
60. Identification and characterization of two distinct truncated forms of gp130 and a soluble form of leukemia inhibitory factor receptor alpha-chain in normal human urine and plasma. Zhang JG, Zhang Y, Owczarek CM, Ward LD, Moritz RL, Simpson RJ, Yasukawa K, Nicola NA, J Biol Chem 1998 273 10798 10805 10.1074/jbc.273.17.10798 9553147
61. Stimulation of leukemia inhibitory factor receptor degradation by extracellular signal-regulated kinase. Blanchard F, Duplomb L, Wang Y, Robledo O, Kinzie E, Pitard V, Godard A, Jacques Y, Baumann H, J Biol Chem 2000 275 28793 28801 10858440
62. Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor alpha, and oncostatin M receptor beta by distinct mechanisms. Blanchard F, Wang Y, Kinzie E, Duplomb L, Godard A, Baumann H, J Biol Chem 2001 276 47038 47045 10.1074/jbc.M107971200 11602599
63. Neuropoietin activates STAT3 independent of LIFR activation in adipocytes. White UA, Stephens JM, Biochem Biophys Res Commun 2010 395 48 50 10.1016/j.bbrc.2010.03.132 20353755
64. Biochemical evaluation of endometrial function at the time of implantation. Lindhard A, Bentin-Ley U, Ravn V, Islin H, Hviid T, Rex S, Bangsbøll S, Sørensen S, Fertil Steril 2002 78 221 233 10.1016/S0015-0282(02)03240-5 12137855
65. Osteoblasts display receptors for and responses to leukemia-inhibitory factor. Allan EH, Hilton DJ, Brown MA, Evely RS, Yumita S, Metcalf D, Gough NM, Ng KW, Nicola NA, Martin TJ, J Cell Physiol 1990 145 110 119 10.1002/jcp.1041450116 2170427
66. Oncostatin-M: a new bone active cytokine that activates osteoblasts and inhibits bone resorption. Jay PR, Centrella M, Lorenzo J, Bruce AG, Horowitz MC, Endocrinology 1996 137 1151 1158 8625883
67. The pleiotropic actions of leukemia inhibitory factor. Gough NM, Williams RL, Cancer Cells 1989 1 77 80 2518284
68. Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia. Bozec A, Bakiri L, Hoebertz A, Eferl R, Schilling AF, Komnenovic V, Scheuch H, Priemel M, Stewart CL, Amling M, Wagner EF, Nature 2008 454 221 225 10.1038/nature07019 18548006
69. Analysis of neuronal and glial phenotypes in brains of mice deficient in leukemia inhibitory factor. Bugga L, Gadient RA, Kwan K, Stewart CL, Patterson PH, J Neurobiol 1998 36 509 524 10.1002/(SICI)1097-4695(19980915)36:4<509:: AID-NEU5>3.0.CO;2-# 9740023
70. Essential function of LIF receptor in motor neurons. Li M, Sendtner M, Smith A, Nature 1995 378 724 727 10.1038/378724a0 7501019
71. IL-6, Leukemia Inhibitory Factor, and Onccostatin M Stimulate Bone Resorption and Regulate the Expression of Receptor Activator of NF-kB Ligand, Osteoprotegerin, and Receptor Activator of NF-kB in Mouse Calvariae. Palmqvist P, Persson E, Conaway HH, Lerner UH, J Immunol 2002 169 3353 3362 12218157
72. Transforming growth factor-{beta} coordinately induces suppressor of cytokine signaling 3 and leukemia inhibitory factor to suppress osteoclast apoptosis. Ruan M, Pederson L, Bradley EW, Bamberger A-M, Oursler MJ, Endocrinology 2010 151 1713 1722 10.1210/en.2009-0813 20181800
73. Biphasic effects of leukemia inhibitory factor on osteoblastic differentiation. Malaval L, Aubin JE, J Cell Biochem Suppl 2001 Suppl 36 63 70 11455571
74. Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. Walker EC, McGregor NE, Poulton IJ, Pompolo S, Allan EH, Quinn JMW, Gillespie MT, Martin TJ, Sims NA, J Bone Miner Res 2008 23 2025 2032 10.1359/jbmr.080706 18665789
75. Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone. Richards CD, Langdon C, Deschamps P, Pennica D, Shaughnessy SG, Cytokine 2000 12 613 621 10.1006/cyto.1999.0635 10843736
76. Neurotrophic effects of leukemia inhibitory factor on neural cells derived from human embryonic stem cells. Majumder A, Banerjee S, Harrill JA, Machacek DW, Mohamad O, Bacanamwo M, Mundy WR, Wei L, Dhara SK, Stice SL, Stem Cells 2012 30 2387 2399 10.1002/stem.1201 22899336
77. Defects in tongue papillae and taste sensation indicate a problem with neurotrophic support in various neurological diseases. Gardiner J, Barton D, Vanslambrouck JM, Braet F, Hall D, Marc J, Overall R, Neuroscientist 2008 14 240 250 18270312
78. Recombinant cholinergic differentiation factor (leukemia inhibitory factor) regulates sympathetic neuron phenotype by alterations in the size and amounts of neuropeptide mRNAs. Nawa H, Nakanishi S, Patterson PH, J Neurochem 1991 56 2147 2150 10.1111/j.1471-4159.1991.tb03479.x 1902872
79. Heart failure causes cholinergic transdifferentiation of cardiac sympathetic nerves via gp130-signaling cytokines in rodents. Kanazawa H, Ieda M, Kimura K, Arai T, Kawaguchi-Manabe H, Matsuhashi T, Endo J, Sano M, Kawakami T, Kimura T, Monkawa T, Hayashi M, Iwanami A, Okano H, Okada Y, Ishibashi-Ueda H, Ogawa S, Fukuda K, J Clin Invest 2010 120 408 421 10.1172/JCI39778 20051627
80. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Pennica D, King KL, Shaw KJ, Luis E, Rullamas J, Luoh SM, Darbonne WC, Knutzon DS, Yen R, Chien KR, Proc Natl Acad Sci USA 1995 92 1142 1146 10.1073/pnas.92.4.1142 7862649
81. Cytokines that signal through the leukemia inhibitory factor receptor-beta complex in the nervous system. Turnley AM, Bartlett PF, J Neurochem 2000 74 889 899 10.1046/j.1471-4159.2000.0740889.x 10693919
82. Leukaemia inhibitory factor (LIF) upregulates excitatory non-adrenergic non-cholinergic and maintains cholinergic neural function in tracheal explants. Knight DA, D'Aprile AC, Spalding LJ, Goldie RG, Thompson PJ, Br J Pharmacol 2000 130 975 979 10.1038/sj.bjp.0703415 10882380
83. Multiple signaling pathways mediate LIF-induced skeletal muscle satellite cell proliferation. Spangenburg EE, Booth FW, Am J Physiol Cell Physiol 2002 283 204 C211 10.1152/ajpcell.00574.2001 12055089
84. bFGF and LIF signaling activates STAT3 in proliferating myoblasts. Megeney LA, Perry RL, LeCouter JE, Rudnicki MA, Dev Genet 1996 19 139 145 10.1002/(SICI)1520-6408(1996)19:2<139::AID-DVG5>3.0.CO;2-A 8900046
85. Leukemia inhibitory factor blocks early differentiation of skeletal muscle cells by activating ERK. Jo C, Kim H, Jo I, Choi I, Jung S-C, Kim J, Kim SS, Jo SA, Biochim Biophys Acta 2005 1743 187 197 10.1016/j.bbamcr.2004.11.002 15843032
86. Leukemia inhibitory factor-dependent increase in myoblast cell number is associated with phosphotidylinositol 3-kinase-mediated inhibition of apoptosis and not mitosis. Hunt LC, Tudor EM, White JD, Exp Cell Res 2010 316 1002 1009 10.1016/j.yexcr.2009.11.022 19962978
87. Oncostatin M is a member of a cytokine family that includes leukemia-inhibitory factor, granulocyte colony-stimulating factor, and interleukin 6. Rose TM, Bruce AG, Proc Natl Acad Sci U S A 1991 88 8641 8645 10.1073/pnas.88.19.8641 1717982
88. The genes for oncostatin M (OSM) and leukemia inhibitory factor (LIF) are tightly linked on human chromosome 22. Rose TM, Lagrou MJ, Fransson I, Werelius B, Delattre O, Thomas G, Jong PJ, Todaro GJ, Dumanski JP, Genomics 1993 17 136 140 10.1006/geno.1993.1294 8406444
89. GP130 cytokines and bone remodelling in health and disease. Sims NA, Walsh NC, BMB Rep 2010 43 513 523 10.5483/BMBRep.2010.43.8.513 20797312
90. Oncostatin m promotes mammary tumor metastasis to bone and osteolytic bone degradation. Bolin C, Tawara K, Sutherland C, Redshaw J, Aranda P, Moselhy J, Anderson R, Jorcyk CL, Genes Cancer 2012 3 117 130 10.1177/1947601912458284 23050044
91. Oncostatin M induces bone loss and sensitizes rat osteosarcoma to the antitumor effect of Midostaurin in vivo. Brounais B, Chipoy C, Mori K, Charrier C, Battaglia S, Pilet P, Richards CD, Heymann D, Rédini F, Blanchard F, Clin Cancer Res 2008 14 5400 5409 10.1158/1078-0432.CCR-07-4781 18765531
92. Cholinergic differentiation factor (CDF/LIF) promotes survival of isolated rat embryonic motoneurons in vitro. Martinou JC, Martinou I, Kato AC, Neuron 1992 8 737 744 10.1016/0896-6273(92)90094-T 1567622
93. Loss of leukemia inhibitory factor receptor beta or cardiotrophin-1 causes similar deficits in preganglionic sympathetic neurons and adrenal medulla. Oberle S, Schober A, Meyer V, Holtmann B, Henderson C, Sendtner M, Unsicker K, J Neurosci 2006 26 1823 1832 10.1523/JNEUROSCI.4127-05.2006 16467531
94. The lack of cardiotrophin-1 alters expression of interleukin-6 and leukemia inhibitory factor mRNA but does not impair cardiac injury response. Gritman K, Winkle DM, Lorentz CU, Pennica D, Habecker BA, Cytokine 2006 36 9 16 10.1016/j.cyto.2006.10.004 17150369
95. Cardiotrophin-1, a cytokine present in embryonic muscle, supports long-term survival of spinal motoneurons. Pennica D, Arce V, Swanson TA, Vejsada R, Pollock RA, Armanini M, Dudley K, Phillips HS, Rosenthal A, Kato AC, Henderson CE, Neuron 1996 17 63 74 10.1016/S0896-6273(00)80281-0 8755479
96. Expression and effects of cardiotrophin-1 (CT-1) in human airway smooth muscle cells. Zhou D, Zheng X, Wang L, Stelmack G, Halayko AJ, Dorscheid D, Bai TR, Br J Pharmacol 2003 140 1237 1244 10.1038/sj.bjp.0705562 14597603
97. Cardiotrophin-1 alters airway smooth muscle structure and mechanical properties in airway explants. Zheng X, Zhou D, Seow CY, Bai TR, Am J Physiol Lung Cell Mol Physiol 2004 287 1165 L1171 10.1152/ajplung.00171.2004 15273080
98. Purification of the chick eye ciliary neuronotrophic factor. Barbin G, Manthorpe M, Varon S, J Neurochem 1984 43 1468 1478 10.1111/j.1471-4159.1984. tb05410.x 6491662
99. Stüve-Wiedemann syndrome and related bent bone dysplasias. Akawi NA, Ali BR, Al-Gazali L, Clin Genet 2012 82 12 21 10.1111/j.1399-0004.2012.01852.x 22300393
100. Ciliary neurotrophic factor inhibits bone formation and plays a sex-specific role in bone growth and remodeling. McGregor NE, Poulton IJ, Walker EC, Pompolo S, Quinn JMW, Martin TJ, Sims NA, Calcif Tissue Int 2010 86 261 270 10.1007/s00223-010-9337-4 20157807
101. Leukaemia inhibitory factor (lif) is expressed in hypertrophic chondrocytes and vascular sprouts during osteogenesis. Grimaud E, Blanchard F, Charrier C, Gouin F, Redini F, Heymann D, Cytokine 2002 20 224 230 10.1006/cyto.2002.2002 12550107
102. Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival. Sheng Z, Pennica D, Wood WI, Chien KR, Development 1996 122 419 428 8625793
103. Differential secretion of the mutated protein is a major component affecting phenotypic severity in CRLF1-associated disorders. Herholz J, Meloni A, Marongiu M, Chiappe F, Deiana M, Herrero CR, Zampino G, Hamamy H, Zalloum Y, Waaler PE, Crisponi G, Crisponi L, Rutsch F, Eur J Hum Genet 2011 19 525 533 10.1038/ejhg.2010.253 21326283
104. gp130 Signaling in bone cell biology: multiple roles revealed by analysis of genetically altered mice. Sims NA, Mol Cell Endocrinol 2009 310 30 39 10.1016/j.mce.2008.08.025 18805458
105. Ciliary neurotrophic factor, cardiotrophin-like cytokine, and neuropoietin share a conserved binding site on the ciliary neurotrophic factor receptor alpha chain. Rousseau F, Chevalier S, Guillet C, Ravon E, Diveu C, Froger J, Barbier F, Grimaud L, Gascan H, J Biol Chem 2008 283 30341 30350 10.1074/jbc.M803239200 18728012
106. Target-dependent specification of the neurotransmitter phenotype: cholinergic differentiation of sympathetic neurons is mediated in vivo by gp 130 signaling. Stanke M, Duong CV, Pape M, Geissen M, Burbach G, Deller T, Gascan H, Otto C, Parlato R, Schütz G, Rohrer H, Development 2006 133 141 150 10.1242/dev.02189 16319110
107. Suckling defect in mice lacking the soluble haemopoietin receptor NR6. Alexander WS, Rakar S, Robb L, Farley A, Willson TA, Zhang JG, Hartley L, Kikuchi Y, Kojima T, Nomura H, Hasegawa M, Maeda M, Fabri L, Jachno K, Nash A, Metcalf D, Nicola NA, Hilton DJ, Curr Biol 1999 9 605 608 10.1016/S0960-9822(99) 80266-8 10359701
108. Cardiotrophin-like cytokine/cytokine-like factor 1 is an essential trophic factor for lumbar and facial motoneurons in vivo. Forger NG, Prevette D, deLapeyrière O, Bovis B, Wang S, Bartlett P, Oppenheim RW, J Neurosci 2003 23 8854 8858 14523086
109. New insights in congenital bowing of the femora. Cormier-Daire V, Geneviève D, Munnich A, Merrer M, Clin Genet 2004 66 169 176 10.1111/j.0009-9163.2004.00307.x 15324311
110. Type IX Ehlers-Danlos syndrome. A new variant with pathognomonic radiographic features. Sartoris DJ, Luzzatti L, Weaver DD, Macfarlane JD, Hollister DW, Parker BR, Radiology 1984 152 665 670 6463246
111. Congenital bowing of long bones: prenatal ultrasound findings and diagnostic dilemmas. Farra C, Piquet C, Guillaume M, D'Ercole C, Philip N, Fetal Diagn Ther 2002 17 236 239 10.1159/000059376 12065952
112. A molecular and clinical study of Larsen syndrome caused by mutations in FLNB. Bicknell LS, Farrington-Rock C, Shafeghati Y, Rump P, Alanay Y, Alembik Y, Al-Madani N, Firth H, Karimi-Nejad MH, Kim CA, Leask K, Maisenbacher M, Moran E, Pappas JG, Prontera P, de Ravel T, Fryns J-P, Sweeney E, Fryer A, Unger S, Wilson LC, Lachman RS, Rimoin DL, Cohn DH, Krakow D, Robertson SP, J Med Genet 2007 44 89 98 10.1136/jmg.2007.051631 16801345
113. Congenital bowing and angulation of long bones. Angle C, Pediatrics 1954 13 257 268 13155074
114. Long-limbed campomelic dwarfism. A radiologic and pathologic study. Austin G, Gold R, Mirra J, Am J Dis Child 1980 134 1035 1042 10.1001/archpedi.1980.02130230015005 7435461
115. Spectrum of SchwartzJampel syndrome includes micromelic chondrodysplasia, kyphomelic dysplasia, and Burton disease. Spranger J, Hall B, Am J Med Genet 2000 94 287 295 10.1002/1096-8628(20001002)94:4<287::AID-AJMG5>3.0.CO;2-G 11038441
116. Long-term follow-up in Stuve-Wiedemann syndrome: a clinical report. Gaspar IM, Saldanha T, Cabral P, Vilhena MM, Tuna M, Costa C, Dagoneau N, Daire VC, Hennekam RCM, Am J Med Genet A 2008 146A 1748 1753 10.1002/ajmg.a.32325 18546280
117. Heterogeneity in Schwartz-Jampel chondrodystrophic myotonia. Giedion A, Pediatr Radiol 1997 27 454 10.1007/s002470050168 9133363
118. Case report of prenatal diagnosis of Stüve-Wiedemann Syndrome in a woman with another child affected too. Catavorello A, Vitale SG, Rossetti D, Caldaci L, Panella MM, J Prenat Med 2013 7 35 38 24175015
119. Valgus slipped capital femoral epiphysis without posterior displacement: two case reports. Shea KG, Apel PJ, Hutt NA, Guarino J, J Pediatr Orthop B 2007 16 201 203 10.1097/BPB.0b013e328010c041 17414782
120. Ocular treatment of children with Stuve-Wiedemann Syndrome. Injarie A, Narang A, Idrees Z, Saggar A, Nischal K, Cornea 2012 31 269 272 10.1097/ICO.0b013e3182182089 22316651
121. Neurotrophic keratitis. Bonini S, Rama P, Olzi D, Lambiase A, Eye (Lond) 2003 17 989 995 10.1038/sj.eye.6700616 14631406
122. Malignant hyperpyrexia in a patient with Schwartz-Jampel syndrome. Seay AR, Ziter FA, J Pediatr 1978 93 83 84 10.1016/S0022-3476(78)80609-X 650352
123. The Schwartz-Jampel syndrome. Its clinical, physiological and histological expressions. Fowler W, Layzer R, Taylor R, Eberle E, Sims G, Munsat T, Philippart M, Wilson B, J Neurol Sci 1974 22 127 146 10.1016/0022-510X(74) 90060-4 4830552